Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
TAOWEAVE INC (TWAV)
NASDAQFinancialsAsset ManagementSnapshot 2026-11-04
$1.27-5.22%
Close 2026-11-04 · 1-day change
NASDAQFinancialsAsset ManagementSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TWAV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
5 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
M&A activity supports growth | A supporting condition in TAOWEAVE INC's published investment case. The stated target is M&A deals completed with positive financial impact within next 4 quarters. | Intact | No material M&A impact or negative M&A outcomes reported | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth case rather than a proven compounder: TWAV is loss-making, recent financial performance is weak, and risk is high. The long-term thesis is in a watch state, with medium confidence and no fresh break in the thesis reported.
The valuation signal is cheap versus peers, but the expectations gap is negative, meaning expectations appear demanding relative to the evidence. The priced-in tag is justified and fragility is low; valuation also fell by 22.3 points recently, though the snapshot does not explain the cause.
Near-term results show revenue declining from $707,000 in 2026-Q1 to $522,000 in 2026-Q2, while operating loss widened from $559,000 to $841,000. A live Avia deployment provides operational evidence for the Manako platform, but commercial contribution is not separately reported; Bittensor activity also lacks separate revenue evidence. Into the next report, erratic earnings surprises and the small-company risk make results worth watching.
Over the multi-year view, the thesis depends on whether Manako deployments and Bittensor ecosystem work turn into measurable revenue and improved operating performance. In the near term, lower rates could weigh on the Financials sector backdrop, while continued strong results from BLK, BX, and KKR could support sector momentum; misses or weaker guidance from those firms could remove that support.
For the next 1 to 3 years, TWAV remains a high-risk, loss-making business with early operational progress but little reported financial proof of its growth initiatives. The thesis hinges on revenue conversion and improved performance, alongside a neutral-to-uncertain sector backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Net income turned positive at $1.7M in 2026-Q1. |
| Intact |
| Net income falls below zero next quarter |
Net income: $-3.29M FY2026-Q2; GAAP. Published target: >=1700000 USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 7, 2026-3,290,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating cash flow improving to at least -$650K next quarter | Cash burn is reducing, with operating cash flow improving from -$980K to -$650K. | Improving | Operating cash flow worsens beyond -$980K next quarter | Cash from operations: $-539,000 FY2026-Q2; GAAP. Published target: >=-650000 USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Jun 30, 2026-539,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating loss narrowing to at least -$559K next quarter | A primary condition in TAOWEAVE INC's published investment case. The stated target is >=-559000 USD. | Intact | Operating loss worsens beyond -$928K next quarter | Operating income: $-841,000 FY2026-Q2; GAAP. Published target: >=-559000 USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 7, 2026-841,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to at least $707K next quarter | A primary condition in TAOWEAVE INC's published investment case. The stated target is >=707000 USD. | Intact | Revenue falls below $563K next quarter | Revenue: $522,000 FY2026-Q2; GAAP. Published target: >=707000 USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 7, 2026522,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-228.00 → $-228.00 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-07-25 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-07-26 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-07-27 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-07-28 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-07-29 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-07-30 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-07-31 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-01 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-02 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-03 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-04 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-05 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-06 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-08 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-09 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-10 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-12 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-13 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-14 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-15 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-16 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-17 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-18 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-19 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-20 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-21 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-22 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-23 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-24 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-25 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-26 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-27 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-28 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-29 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-30 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-08-31 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-01 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-02 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-03 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-04 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-05 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-06 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-07 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-08 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-09 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-10 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-11 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-12 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-13 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-14 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-15 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-16 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-17 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-18 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-19 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-20 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-21 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-22 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-23 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-24 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-25 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-26 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-27 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-28 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-29 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-09-30 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-01 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-02 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-03 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-04 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-05 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-06 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-07 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-08 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-09 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-10 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-11 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-12 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-13 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-14 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-15 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-16 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-17 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-18 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-19 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-20 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-21 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-22 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-23 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-24 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-25 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-26 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-27 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-28 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-29 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-30 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-10-31 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-11-01 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-11-02 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-11-03 | $-228.00 | $7,486,000 | 1 / 1 |
| 2026-11-04 | $-228.00 | $7,486,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings5 of 5 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.